Sugi Predict

Sugi Predict / Compounds / SCHEMBL20745653

SCHEMBL20745653

SCHEMBL20745653

O=S(=O)(Cc1cc(Cl)n(C(c2ccccc2)(c2ccccc2)c2ccccc2)n1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ MCOLN3 Q8TDD5 1/20 0.45
▸ HTT P42858 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ ALDH1A1 P00352 5/20 0.39
▸ SMN1; SMN2 Q16637 6/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.38
▸ NPC1 O15118 4/20 0.37
▸ RAB9A P51151 4/20 0.37
▸ LMNA P02545 2/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ PSIP1 O75475 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20745930 0.77 P2RX7 (0.36) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL20746056 0.76 SLC16A3 (0.34) CYP1A2CYP2C19
SCHEMBL27604945 0.68 KCNN4 (0.34) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL20361623 0.68 KCNN4 (0.34) KMT2AMEN1MAPTHTTSMN1; SMN2
SCHEMBL3085048 0.65 KMT2A (0.71) KMT2AMEN1MAPTMCOLN3HTT
SCHEMBL31555672 0.64 ALDH1A1 (0.46) KMT2AMEN1MAPTMCOLN3HTT
SCHEMBL20746109 0.63 GAA (0.46) KMT2AMAPTALDH1A1LMNACYP1A2
SCHEMBL31555655 0.63 ALDH1A1 (0.51) KMT2AMEN1MAPTMCOLN3HTT
SCHEMBL23992857 0.62 KMT2A (0.48) KMT2AMEN1MAPTMCOLN3HTT
SCHEMBL28947746 0.62 MEN1 (0.48) KMT2AMEN1MAPTMCOLN3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11957680-B2 Pyruvate kinase activators for use in treating blood disorders AGIOS PHARMACEUTICALS, INC. (US) 2024-04-16 — — US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 — — US disclosed
US-11872225-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2024-01-16 — — US disclosed
EP-3668881-B1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS INC (US) 2023-10-04 — — EP disclosed
CN-111032046-B Pyruvate kinase modulators and uses thereof 安吉奥斯医药品有限公司 2023-09-26 — — CN disclosed
EP-3668512-B1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS INC (US) 2023-02-15 — — EP disclosed
US-20220395503-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2022-12-15 — — US disclosed
US-11464775-B2 Pyruvate kinase modulators and use thereof AGIOS PHARMACEUTICALS, INC. (US) 2022-10-11 — — US disclosed
US-20220233541-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS, INC. 2022-07-28 — — US disclosed
US-11364240-B2 Pyruvate kinase activators for use in treating blood disorders AGIOS PHARMACEUTICALS, INC. (US) 2022-06-21 — — US disclosed
US-20210130371-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. 2021-05-06 — — US disclosed
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS, INC. (US) 2020-07-02 — — US disclosed
EP-3668881-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS Agios Pharmaceuticals, Inc. (US) 2020-06-24 — — EP disclosed
EP-3668512-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF Agios Pharmaceuticals, Inc. (US) 2020-06-24 — — EP disclosed
CN-111032046-A Pyruvate kinase modulators and uses thereof 安吉奥斯医药品有限公司 2020-04-17 — — CN disclosed
WO-2019035863-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS AGIOS PHARMACEUTICALS, INC. (US) 2019-02-21 — — WO disclosed
WO-2019035865-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS INC. (US) 2019-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11872225-B2 Pyruvate kinase modulators and use thereof PDK1, PDK2, PDK4 KMT2A 701/4885MEN1 2619/4885MAPT 3874/4885
US-11364240-B2 Pyruvate kinase activators for use in treating blood disorders PDK1, PDK2, PDK3 KMT2A 578/4885MEN1 3431/4885MAPT 3448/4885
US-20210130371-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 KMT2A 578/4885MEN1 3431/4885MAPT 3448/4885
US-20200206225-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF PDK1, PDK2, PDK4 KMT2A 701/4885MEN1 2619/4885MAPT 3874/4885
US-20220233541-A1 PYRUVATE KINASE MODULATORS AND USE THEREOF PDK1, PDK2, PDK4 KMT2A 701/4885MEN1 2619/4885MAPT 3874/4885
US-20220395503-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS PDK1, PDK2, PDK3 KMT2A 578/4885MEN1 3431/4885MAPT 3448/4885
US-11464775-B2 Pyruvate kinase modulators and use thereof PDK1, PDK2, PDK4 KMT2A 701/4885MEN1 2619/4885MAPT 3874/4885
US-11957680-B2 Pyruvate kinase activators for use in treating blood disorders PDK1, PDK2, PDK3 KMT2A 578/4885MEN1 3431/4885MAPT 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.